*Studied in patients since 2007. FDA approved for moderate to severe PsO in 2015 and for active PsA and AS in 2016.
†IQVIA National Prescription Audit TRxs as reported in SMART US Edition. TRxs represent national projected prescription for all indications. IQVIA was formarly named IMS Health.
‡Across PsO, PsA, and AS indications.
AS=ankylosing spondylitis; IL=interleukin; PsA=psoriatic arthritis; PsO=plaque psoriasis.
References: 1. COSENTYX [prescribing information] East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2021. 2. Data on file. IQVIA National Prescription Audit TRxs as reported in SMART US Edition. Novartis Pharmaceuticals Corp; January 6, 2021 3. Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008. 4. Bissonnette R et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acd Dermatol Veneraol. 2018; 32(9):1507-1514. 5. Data on file. CAIN457A2304E1 Clinical Study Report. Novartis Pharmaceuticals Corp; February 2018. 6. Data on file. CAIN457F2312 (FUTURE 2) 5-Year Interim Report_May 2019. 7. Date on file. IQVIA un-projected patient counts. Internal communication, Roopal Jain, email@example.com, January 6, 2021. 8. Kane D et al. A prospective, clinical and radiological study of early psoriatic arthritis; an early synovitis clinic experience. Rheumatology. 2003;42:1460-1468. 9. Brembilla NC et al. The Il-17 family of cytokines i psoriasis: IL-17A and beyond. Front Immunol.2018;9:1682. doi:10.3389/fimmu.2018.01682. 10. Nestile FO et al. Psoriasis. N Engl J Med. 2099;361(5):496-509. 11. Bronckers IMGJ et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373-384. 12. Karimi K et al. Pediatric psoriasis: a rebiew. J Dermatolog Clin Res. 2018;6(3):1123. 13. Menter A et al. Joint American Academy of Dermatology- National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis i pediatric patients. J Am Acad Dermatol. 2020;82(1): 161-201. 14. Eichenfield LF et al. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol. 2018;35:17-181. 15. Data on file. CAIN457A2310 Clinical Study Report. Week 24 Analysis. Novartis Pharmaceuticals Corp; July 2018. 16. Data o file. CAIN457A2311 Clinical Study Report.Week 24 Analysis. Novartis *harmaceuticals Corp; September 2019. 17. Data on file. CAIN457A2310 Clinical Study Report. Week 52 Analysis. Novartis Pharmaceuticals Corp; September 2019.